Amgen (AMGN) has been the subject of multiple news articles, primarily related to its drug,
Tarlatamab, receiving
FDA Approval for small cell lung cancer. The news follows
FDA's priority review of their request, making it the first T-cell engager therapy for this condition. This approval has positively impacted the company's stock, causing its relative strength (RS) rating to jump 81. Other noteworthy mentions involve a promising experimental obesity drug causing an uptick in investor attention. Amgen's Q1 Financial Results exceeded expectations, with
stock soaring on drug updates. Despite the company topping earnings per share (EPS) with successful Q1 results, some analysts predict a decline in earnings. However, there's continued optimism towards the company's innovative drug, especially in obesity treatment. It also revealed details of its dividend growth rate and debt-to-equity ratio. The company announced significant strategic changes, including new executive appointments and the opening of a biomanufacturing site in Ohio. Lastly, the company is seen as a trending stock with a firm hold recommendation.
Amgen AMGN News Analytics from Tue, 24 Oct 2023 07:00:00 GMT to Fri, 17 May 2024 23:04:00 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor -3
